Trials
3 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ankylosing Spondylitis, Axial Spondyloarthritis, Non-Radiographic, Axial Spondyloarthritis
- Main trialPhase 3
- “This study will evaluate the efficacy and safety of 608 in patients with AS.”In the company’s words, NCT07261644 on ClinicalTrials.gov
- Other names
- 608 dose
Other drugs for Ankylosing Spondylitis
- LNK01001Lynk Pharmaceuticals Co., Ltd · Phase 3
- JitongningTasly · Phase 3
- HS_SW01 cellsShenzhen Huishan Biotechnology Co., Ltd. · Phase 1/2
- VilamakitugXBiotech, Inc. · Phase 2
- HB0017Huahai Pharmaceutical (Huaota) · Phase 1
- Human Umbilical Cord Mesenchymal Stem CellsAsia Cell Therapeutics (Shanghai) Co., Ltd. · Phase 1
Coming up2
- 14 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 19 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 14 Jan 2027 | A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | |
| Phase 3Not yet recruiting | 19 Apr 2028 | A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) | |
| Phase 2Recruiting | 22 Sep 2025 | A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) | |
| Phase 2Unknown | May 2023 | A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026